Expert Opinion on Drug Metabolism & Toxicology

Article	Citations
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins	77
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer	67
Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity	59
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders	53
Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials	44
Albumin-based drug designs for pharmacokinetic modulation	43
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion	43
Prodrugs and nanomicelles to overcome ocular barriers for drug penetration	42
High-throughput PBTK models for in vitro to in vivo extrapolation	41
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?	37
Antibiotic resistance propagation through probiotics	36
Analyzing FDA-approved drugs for compliance of pharmacokinetic principles: should there be a critical screening parameter in drug designing protocols?	35
Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advancedin vitrotesting	34
Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease	34
The pharmacokinetics of antibiotics in cystic fibrosis	33
Alterations in drug disposition in older adults: a focus on geriatric syndromes	32
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity	30
The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis	30
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease	28
Drug metabolism in the lungs: opportunities for optimising inhaled medicines	27
Tumor grafted – chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation	27
Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems	26
Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis	25
Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy	24
Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs	23

Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?	23
In silico models for genotoxicity and drug regulation	23
Assessing the therapeutic potential and toxicity of Mitragyna speciosa in opioid use disorder	23
Genetic risk factors in the development of idiosyncratic drug-induced liver injury	22
Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity	21
SULT genetic polymorphisms: physiological, pharmacological and clinical implications	21
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review	21
Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization	21
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies	20
Novel strategies for the treatment of acetaminophen hepatotoxicity	19
Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients	19
Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives	19
An update on the use of inositols in preventing gestational diabetes mellitus (GDM) and neural tube defects (NTDs)	18
ADME and toxicity considerations for tramadol: from basic research to clinical implications	18
Pharmacogenetic factors affecting β-blocker metabolism and response	18
MDMA interactions with pharmaceuticals and drugs of abuse	18
Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity	18
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	17
New clinical targets of d-chiro-inositol: rationale and potential applications	17
Retinoic acid receptor-targeted drugs in neurodegenerative disease	17
PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches	17
Potential statin drug interactions in elderly patients: a review	16
Renal and non-renal response of ABC and SLC transporters in chronic kidney disease	16
Ingestion-time – relative to circadian rhythms – differences in the pharmacokinetics and pharmacodynamics of hypertension medications	16
Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity	16
GenotypingHLAalleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art	16
Soft drugs: design principles, success stories, and future perspectives	16
An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome	15
Role of SLC transporters in toxicity induced by anticancer drugs	15
A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients	14
Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse	14
An update on drug–drug interactions between antiretroviral therapies and drugs of abuse in HIV systems	14
Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis	14
Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion	14
Assessing the pharmacokinetics and toxicology of polymeric micelle conjugated therapeutics	14
Genetic factors influencing the development of vincristine-induced neurotoxicity	13
The role of cytochrome P450 (CYP) enzymes in hyperoxic lung injury	13
Novel test strategies for in vitro seizure liability assessment	13
Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials	13
Transporter–enzyme interplay and the hepatic drug clearance: what have we learned so far?	13
Clinically relevant endothelial nitric oxide synthase polymorphisms and their impact on drug response	13
Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia	12
The regulation of liver cytochrome P450 expression and activity by the brain serotonergic system in different experimental models	12
Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation	12
Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management	12
Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis	12
Coffee in cancer chemoprevention: an updated review	11
An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects	11
Positioning the new drugs for migraine	11
Pharmacogenomics in Asians: Differences and similarities with other human populations	11

Drug-drug interactions between psychotropic medications and oral contraceptives	11
Current approaches and future strategies for the implementation of pharmacogenomics in the clinical use of azole antifungal drugs	11
Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs	11
Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals and Direct Acting Antivirals	11
Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale	11
Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management	11
Novel models for the prediction of drug–gene interactions	11
Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review	10
Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjec	10
Machine learning models in the prediction of drug metabolism: challenges and future perspectives	10
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships	10
Circadian regulation of transporter expression and implications for drug disposition	10
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis	10
Xanthones as P-glycoprotein modulators and their impact on drug bioavailability	10
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia	10
An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity	10
Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs	10
Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism	10
Modeling drug transport within the viable skin - a review	10
Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer	10
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature	9
Inositols in the ovaries: activities and potential therapeutic applications	9
Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy	9
Xanthones from Securidaca inappendiculata antagonized the antirheumatic effects of methotrexate in vivo by promoting its secretion into urine.	9
Evaluating the risk of manganese-induced neurotoxicity of parenteral nutrition: review of the current literature	9
Pharmacokinetic considerations about antiseizure medications in the elderly	9
Evolving approaches on measurements and applications of intracellular free drug concentration and Kpuu in drug discovery	9
Pharmacokinetics of current and emerging treatments for hypercholesterolemia	9
Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated	9
Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection	8
An update on drug–drug interactions associated with proton pump inhibitors	8
Exposure to antibiotics during pregnancy alters offspring outcomes	8
Modeling drug-induced liver injury: current status and future prospects	8
Restoration and stabilization of acrylamide-induced DNA, mitochondrial damages and oxidative stress by chrysin in human lymphocyte	8
Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects	8
Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence	8
The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions	8
Clopidogrel drug interactions: a review of the evidence and clinical implications	8
An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables	8
Refining in vitro and in silico neurotoxicity approaches by accounting for interspecies and interindividual differences in toxicodynamics	7
An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease	7
Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties	7
The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV	7
Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice	7
A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers	7
An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies	7
Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics	7
Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa	7
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study	7
Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease	7
Understanding mechanisms of drug resistance in epilepsy and strategies for overcoming it	7
Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies	7
Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more	7
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature	7
Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics	6
A review of novel biomarkers and imaging techniques for assessing the severity of chemotherapy-induced peripheral neuropathy	6
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis	6
Toward regulatory acceptance and improving the prediction confidence of in silico approaches: a case study of genotoxicity	6
Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties	6
The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients	6
Inhibition effect of epigallocatechin-3-gallate on the pharmacokinetics of calcineurin inhibitors, tacrolimus, and cyclosporine A, in rats	6
Assessment of the genotoxic potential of a migraine-specific drug by comet and cytokinesis-block micronucleus assays	6
Are we still on the right path(way)?: the altered expression of the pentose phosphate pathway in solid tumors and the potential of its inhibition in combination therapy	6
A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers	6
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	6
A review on the clinical pharmacokinetics of hydralazine	5
AMPK activators for the prevention and treatment of neurodegenerative diseases	5
Strategies for enhancing the oral bioavailability of cannabinoids	5
A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera	5
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria	5
Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment	5
Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population	5
Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: part 2. development of oral dosage formulations	5
Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors	5
Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates	5
Absorption, distribution, metabolism and excretion of hyaluronic acid during pregnancy: a matter of molecular weight	5
Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients	5
A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer	5
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies	5
Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units	4

What have we learned from animal models of idiosyncratic, drug-induced liver injury?	4
Individualizing doses of antiepileptic drugs	4
Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens	4
Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects	4
Brivaracetam for the treatment of focal-onset seizures: pharmacokinetic and pharmacodynamic evaluations	4
Local anesthetics and erector spinae plane blocks: a spotlight on pharmacokinetic considerations and toxicity risks	4
Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug–drug interaction in healthy adults and its extrapolation to virtual chronic	4
Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties	4
Drug–drug interactions involving antipsychotics and antihypertensives	4
Recent lessons learned from population pharmacokinetic studies of mycophenolic acid: physiological, genomic, and drug interactions leading to the prediction of drug effects	4
CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia	4
Ceftazidime dosing in obese patients: is it time for more?	4
Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults	4
Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions	4
Pharmacodynamic and safety considerations for influenza vaccine and adjuvant design	4
Biology and therapeutic applications of the proton-coupled folate transporter	4
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview	3
Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis	3
Can dantrolene be used in the treatment of cardioglycosides poisonings?	3
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition	3
Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics	3
Managing intoxications with nicotine-containing e-liquids	3
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	3
Comorbidities and the right dose: antipsychotics	3
What might the presence of ‘orphan’ CYP450 isoforms in breast epithelial cells mean for the future of targeted therapeutics?	3
Comparing the pharmacokinetics of extended-release tacrolimus (LCP-TAC) to immediate-release formulations in kidney transplant patients	3
Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction	3
Current strategies for predicting side effects from second generation antipsychotics in youth	3
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach	3
Therapeutic drug monitoring in developing nations: assessing the current state of affairs in South America	3
Organotypic-liver slide culture systems to explore the role of extracellular vesicles in pancreatic cancer metastatic behavior and guide new therapeutic approaches	3
Prescription of statins and pharmacokinetic interactions in Colombian patients	3
The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics	3
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	3
Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review	3
A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database	3
Updated pharmacokinetic considerations for the use of antimalarial drugs in pregnant women	3
The influence of cardiopulmonary bypass on pediatric pharmacokinetics	3
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	3
Pharmacokinetics during therapeutic hypothermia in neonates: from pathophysiology to translational knowledge and physiologically-based pharmacokinetic (PBPK) modeling	3
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease	3
The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions	3
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	3
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia	3
Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review	3